Glenmark Therapeutics has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 percent (OTC) compared to the active ingredient in Pataday Twice Daily Relief.

According to Nielsen syndicated data for the latest 52-week period ending July 13, 2024, the Pataday Twice Daily Relief (OTC) market achieved annual sales of approximately USD 26.4 million.

Commenting on the launch, Fabio Moreno, Head, OTC Sales & Marketing, Glenmark Pharmaceuticals Inc., said, “We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1 percent, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this.